Reference : Oncological Applications of Positron Emission Tomography with Fluorine-18 Fluorodeoxy...
Scientific journals : Article
Human health sciences : Oncology
Human health sciences : Radiology, nuclear medicine & imaging
http://hdl.handle.net/2268/10041
Oncological Applications of Positron Emission Tomography with Fluorine-18 Fluorodeoxyglucose
English
Rigo, Pierre mailto [Université de Liège - ULg > Département des sciences de la motricité > Pathologie générale et médecine nucléaire >]
Paulus, Patrick [> > > >]
Kaschten, Bruno [> > > >]
Hustinx, Roland mailto [Université de Liège - ULg > Département des sciences cliniques > Médecine nucléaire]
Bury, Thierry mailto [Université de Liège - ULg > Département des sciences de la motricité > Physiologie humaine et physiologie de l'effort physique]
Jerusalem, Guy mailto [Centre Hospitalier Universitaire de Liège - CHU > > Oncologie médicale >]
Benoit, Thérèse [> > > >]
Foidart-Willems, Jacqueline mailto [> > > >]
Dec-1996
European Journal of Nuclear Medicine
23
12
1641-74
Yes (verified by ORBi)
International
0340-6997
[en] Positron emission tomography ; FDG ; Oncology
[en] Positron emission tomography (PET) is now primarily used in oncological indication owing to the successful application of fluorine-18 fluorodeoxyglucose (FDG) in an increasing number of clinical indications at different stages of diagnosis, and for staging and follow-up. This review first considers the biological characteristics of FDG and then discusses methodological considerations regarding its use. Clinical indications are considered, and the results achieved in respect of various organs and tumour types are reviewed in depth. The review concludes with a brief consideration of the ways in which clinical PET might be improved.
http://hdl.handle.net/2268/10041

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Open access
Rigo P et al, Eur J Nucl Med 1996.pdfPublisher postprint5.54 MBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.